Abstract
As hospital reports of strains of resistant bacteria are continuing to increase, a new approach is required for the identification of small molecules with antibacterial activity. Natural products that bind covalently to their biological target have been largely unexplored, although in the field of cancer chemotherapy, such molecules have been shown to counter resistance developed through efflux mechanisms. The azinomycins are potent antitumour agents that alkylate DNA and one of the natural products, compound 1, is a mono-alkylator that has been reported to retain potent antitumour activity. All four diastereomers of 1 were synthesized via a route involving late stage introduction of the epoxide stereocentre and separation of the resulting compounds. A non-alkylating analogue and a potential alkylator that cannot intercalate were also made. All four diastereomers are potent antibacterial agents in cell lines containing efflux-based resistance mechanisms. MIC values in the range of 0.25-1.0 μg/ml were observed. Comparison with the antitumour activity of the compounds suggests that the antibacterial activity stems from a similar mechanism of action involving DNA alkylation. As the ultimate molecular target of the azinomycins is unknown, bacterial strains may represent an interesting route for the discovery of the downstream mechanisms affected by DNA alkylation.
Keywords: P-glycoprotein efflux pump, cytotoxicity, anti-bacterial activity, Sharpless Asymmetric Epoxidation, column chromatography
Medicinal Chemistry
Title: Antitumour Antibiotics with Potent Activity Against Multidrug Resistant (MDR) Staphylococcus aureus: A New Approach to Targeting Resistant Bacteria
Volume: 1 Issue: 6
Author(s): M. A. Casely-Hayford, N. O. Kerr, E. Smith, S. Gibbons and M. Searcey
Affiliation:
Keywords: P-glycoprotein efflux pump, cytotoxicity, anti-bacterial activity, Sharpless Asymmetric Epoxidation, column chromatography
Abstract: As hospital reports of strains of resistant bacteria are continuing to increase, a new approach is required for the identification of small molecules with antibacterial activity. Natural products that bind covalently to their biological target have been largely unexplored, although in the field of cancer chemotherapy, such molecules have been shown to counter resistance developed through efflux mechanisms. The azinomycins are potent antitumour agents that alkylate DNA and one of the natural products, compound 1, is a mono-alkylator that has been reported to retain potent antitumour activity. All four diastereomers of 1 were synthesized via a route involving late stage introduction of the epoxide stereocentre and separation of the resulting compounds. A non-alkylating analogue and a potential alkylator that cannot intercalate were also made. All four diastereomers are potent antibacterial agents in cell lines containing efflux-based resistance mechanisms. MIC values in the range of 0.25-1.0 μg/ml were observed. Comparison with the antitumour activity of the compounds suggests that the antibacterial activity stems from a similar mechanism of action involving DNA alkylation. As the ultimate molecular target of the azinomycins is unknown, bacterial strains may represent an interesting route for the discovery of the downstream mechanisms affected by DNA alkylation.
Export Options
About this article
Cite this article as:
Casely-Hayford A. M., Kerr O. N., Smith E., Gibbons S. and Searcey M., Antitumour Antibiotics with Potent Activity Against Multidrug Resistant (MDR) Staphylococcus aureus: A New Approach to Targeting Resistant Bacteria, Medicinal Chemistry 2005; 1 (6) . https://dx.doi.org/10.2174/157340605774598126
DOI https://dx.doi.org/10.2174/157340605774598126 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation
Current Pharmacogenomics and Personalized Medicine Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Pharmacokinetics and Pharmacodynamics of Oseltamivir in Neonates, Infants and Children
Infectious Disorders - Drug Targets Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology